Bioweapons of tumor mass destruction?
Dyer
Martin J S
MJ
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD / Q000276:immunology*; D000944:Antigens, Differentiation, B-Lymphocyte / Q000276:immunology*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015815:Cell Adhesion Molecules; D016503:Drug Delivery Systems; D006801:Humans; D037102:Lectins / Q000276:immunology*; D008223:Lymphoma / Q000628:therapy; D009369:Neoplasms / Q000628:therapy*; D051918:Sialic Acid Binding Ig-like Lectin 2
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D000944:Antigens, Differentiation, B-Lymphocyte; D000970:Antineoplastic Agents; C497867:CD22 protein, human; D015815:Cell Adhesion Molecules; D037102:Lectins; D051918:Sialic Acid Binding Ig-like Lectin 2; C448700:epratuzumab